| Patient number | No. of untreated attacks* | Mean duration of untreated attacks (hrs) | No. of treated attacks | No. of attacks treated with 500 IU/1000 IU/1500 IU/3000 IU pdC1-INH | Mean time between attack onset and injection of icatibant (hrs) | Mean time to first symptom relief (hrs) | Mean duration of treated attacks (hrs) | Mean shortening of attack duration attacks (%) | No. of attacks shortened by > 50% | No. of attacks shortened by 20–50% | No. of attacks shortened by < 20% |
|---|
| Facial attacks |
| 1 | 10 | 47.6 | 20 | 4/16/0/0 | 1.7 | 2.6 | 45.3 | 4.8 | 0 | 0 | 20 |
| 2 | 10 | 105.1 | 6 | 6/0/0/0 | 3.3 | 1 | 18 | 82.9 | 6 | 0 | 0 |
| 14 | 10 | 67.1 | 1 | 0/1/0/0 | 2.5 | 1 | 24 | 64.2 | 1 | 0 | 0 |
| Tongue swellings |
| 1 | 10 | 36.4 | 3 | 0/3/0/0 | 4 | 5 | 30 | 17.6 | 0 | 0 | 3 |
| 4 | 10 | 17.3 | 4 | 2/0/1/1 | 1 | 0.3 | 54.5** | 0 | 0 | 0 | 4 |
| 15 | 10 | 2.7 | 1 | 1/0/0/0 | 2 | 0.5 | 1 | 62.7 | 1 | 0 | 0 |
| 16 | 10 | 34.2 | 6 | 6/0/0/0 | 2 | 1 | 12 | 64.5 | 5 | 1 | 0 |
| 17 | 3 | 48 | 2 | 0/1/1/0 | 6 | 1 | 21 | 56.3 | 2 | 0 | 0 |
| 18 | 6 | 96 | 2 | 0/2/0/0 | 0.5 | 0.2 | 12 | 87.5 | 2 | 0 | 0 |
| 19 | 10 | 24.4 | 1 | 0/1/0/0 | 2 | 1 | 6 | 75.4 | 1 | 0 | 0 |
| 20 | 10 | 20.8 | 1 | 0/1/0/0 | 2 | 24 | 48** | 0 | 0 | 0 | 1 |
| Abdominal attacks |
| 1 | 10 | 27.7 | 12 | 2/10/0/0 | 0.2 | 3.6 | 26.3 | 5.1 | 0 | 2 | 10 |
| 21 | 10 | 84.3 | 5 | 0/5/0/0 | 24 | 0.4 | 60.2 | 28.6 | 3 | 0 | 2 |
| 22 | 10 | 81.9 | 10 | 0/10/0/0 | 2.5 | 1 | 22.2 | 72.9 | 8 | 2 | 0 |
| Total No. | 129 | – | 74 | 21/50/2/1 | – | – | – | – | 29 | 5 | 40 |
- HAE hereditary angioedema, HAE-PLG HAE with normal C1-INH and the c.988A > G (p.K330E) variant in the plasminogen gene; pdC1-INH plasma-derived C1-INH, No. number
- *Last 10 attacks before treatment or all if less than 10
- **Severe and rapidly developing attacks
- Note: Out of the 74 swellings, 27 were facial swellings, 20 tongue swellings, and 27 abdominal attacks
